Table 1. Demographic and Immunohistochemical Features.
| Characteristic (Nā=ā63) | Data |
|---|---|
| Age, median (range), y | 67 (49-87) |
| Sex, No. (%) | |
| Male | 36 (57) |
| Female | 27 (43) |
| Tumor size, median (range), cm | 3.0 (0.3-9.5) |
| Grade, No. (%) | |
| Well differentiated | 3 (5) |
| Moderately differentiated | 24 (38) |
| Poorly differentiated | 34 (54) |
| Perineural invasion present | 39 (62) |
| Lymphovascular invasion present | 28 (44) |
| Margin, No. (%) | |
| R0 | 43 (68) |
| R1 (ā¤1 mm) | 20 (32) |
| Nodal metastases, median (range), No. | 2 (0-11) |
| T stage, No. (%) | |
| 1 | 12 (19) |
| 2 | 38 (60) |
| 3 | 13 (21) |
| N stage, No. (%) | |
| 0 | 15 (24) |
| 1 | 29 (46) |
| 2 | 19 (30) |
| TNM stage, No. (%)a | |
| 1a | 6 (10) |
| 1b | 6 (10) |
| 2a | 3 (5) |
| 2b | 29 (46) |
| 3 | 19 (30) |
| Adjuvant chemotherapy administered, No. (%) | 44 (70) |
| Adjuvant radiation therapy administered, No. (%) | 16 (25) |
| Vital status, No. (%) | |
| Deceased | 51 (81) |
| Alive | 12 (19) |
| Overall survival, median (IQR), mo | 19.7 (12.8-35.8) |
| Kaplan-Meier survival estimates, % (95% CI) | |
| 2 y | 41.3 (29.1-53.0) |
| 5 y | 15.6 (7.1- 27.2) |
| Intratumoral stainingb | |
| CD8+, median (range), cells/mm2 | 0.23 (0.05-0.69) |
| CD3+, median (range), cells/mm2 | 0.47 (0.14-1.30) |
| CD68+, median (range), cells/mm2 | 0.43 (0.14-1.33) |
| PD-L1 positive, median (range), % | 0.1 (0.01-1.47) |
Abbreviations: IQR, interquartile range; PD-L1, programmed cell death ligand 1.
a
Indicates the American Joint Commission on Cancer Cancer Staging Manual, 8th edition.
b
Data were available for 53 patients.